Jefferies maintains inVentiv at buy

inVentiv Health, Inc. was kept at buy and $34.50 price target by Jefferies & Co., Inc. analyst David Windley. Strong results for the Communication and Clinical segments, bolstered by new wins, lead to an optimistic outlook. The company's earnings per share of $0.34 beat Jefferies' estimate by 2 cents. Shares of the Somerset, N.J.-based commercialization services company were up 14 cents, or 0.47%, at $30.02, on volume of 377,341 shares versus the three-month running average of 278,835 shares. (Nasdaq: VTIV)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.